Clinical Trials Browser

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT03488810 2020-08-17

ARN-509

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Phase 3 Withdrawn

Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT03298958 2019-06-12

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

Phase 3 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT02438852 2019-04-16

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

Phase 3 Withdrawn

Genitourinary

Urinary Bladder Neoplasms, Pain, Postoperative

NCT03693573 2018-11-15

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3 Withdrawn

Genitourinary

Carcinoma, Renal Cell

NCT02053311 2018-07-30

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02471495 2018-05-07

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01762592 2017-12-22

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Phase 3 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00061178 2016-10-19

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Phase 3 Withdrawn

Genitourinary

Carcinoma, Renal Cell

NCT00691899 2016-08-12

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00041171 2016-07-12

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Phase 3 Withdrawn

BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT02260349 2016-03-10

Interest of Indocyanine Green in Neoplastic Prostatic Tissue

Phase 3 Withdrawn

Genitourinary

Margins of Excision, Prostatic Neoplasms

NCT02254915 2015-04-01

SHTC-EUROPE-1

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01214291 2013-11-15

TREAT2

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms, Fractures, Bone

NCT00043212 2013-05-01

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Phase 3 Withdrawn

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00258466 2013-04-08

Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00728533 2011-03-18

Open-Label, Randomised Parallel-Group Study

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

Clinical Trials

RESCUE

KATANA E3M

KATANA E6M

A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial

CARE

Pioglitazone and Insulin Resistance in ADT

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

ARN-509

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Retreatment

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Interest of Indocyanine Green in Neoplastic Prostatic Tissue

SHTC-EUROPE-1

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

TREAT2

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer

Open-Label, Randomised Parallel-Group Study